Perthera

The page discusses rising use of molecular tumor profiling to match patients with targeted therapies and references a report published in the British Journal of Cancer.

Perthera will serve as the centralized “Molecular CRO” under the umbrella protocol for the Target Panc Program, which brings clinical trials to cancer patients throughout the country.

New York, NY // GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.

New York, NY & McLean, VA // Massive Bio has announced a partnership with Perthera.ai. Perthera.ai’s ranked therapy recommendations will complement Massive Bio’s screening and analysis to aid more cancer patients in finding an appropriate clinical trial.

Perthera and PathGen Diagnostik Teknologi announced a strategic partnership aimed at expanding access to cancer care across Indonesia, combining AI-driven treatment intelligence with local infrastructure and clinical expertise.

George Mason University Professor, School Of Systems Biology Co-Director, Center For Applied Proteomics And Molecular Medicine.

Perthera, Inc., is the leading Healthcare Artificial Intelligence company advancing precision medicine through the Perthera Precision Oncology Platform.

Perthera Inc's website privacy policy explains its information collection, use, and visitor options and addresses protected health information under the Health Insurance Portability Accountability Act and related regulations.